brepocitinib

Brepocitinib is an orally available, selective small molecule inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), developed for the treatment of various autoimmune and inflammatory diseases. By selectively binding to and inhibiting TYK2 and JAK1, brepocitinib disrupts cytokine signaling pathways that are critical in mediating immune responses, inflammation, and hematopoiesis. This dual inhibition is designed to reduce inflammatory responses implicated in diseases such as dermatomyositis, uveitis, Crohn's disease, hidradenitis suppurativa, systemic lupus erythematosus (SLE), psoriasis, psoriatic arthritis, ulcerative colitis, alopecia areata, vitiligo, atopic dermatitis, and lupus vulgaris. Brepocitinib has demonstrated statistically significant efficacy in multiple phase II studies across several indications. It is being developed by Priovant Therapeutics (a joint venture between Roivant Sciences and Pfizer) with Pfizer as the originator[3][4][5][6][8].

Brand names

Lisraya

Other names

brepocitinib tosylate